Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$3.9B
160M shares
52-week range
$12.00 – $26.87
86% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
P/S (TTM)
12.7
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
www.adaptivebiotech.comNo one on the platform currently holds ADPT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 239,800 | $3.3M |
| Bridgewater Associatesas of 2026-03-31 | 89,707 | $1.2M |
No one on the platform has traded ADPT yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 54.8% | 23.0% | ||||
| Profit Margin % | -21.5% | -97.0% | ||||
| Free Cash Flow Margin % | -17.7% | -88.8% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $293M | +10.2% | $-0.55 | $-0.56–$-0.53 | — | 6 |
| 2027 | $358M | +22.2% | $-0.18 | $-0.22–$-0.12 | — | 6 |
| 2028 | $439M | +22.5% | $0.02 | $-0.16–$0.12 | 1548.8× | 5 |
| 2029 | $545M | +24.0% | $0.23 | $0.22–$0.24 | 107.7× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | $-0.13 | $-0.25 | -87.1% |
| 2026-05-05 | $-0.16 | $-0.13 | +18.8% |
| 2026-02-05 | $-0.19 | $-0.09 | +52.6% |
| 2025-11-06 | $-0.18 | $0.06 | +133.3% |
| 2025-08-05 | $-0.24 | $-0.17 | +29.2% |
| 2025-05-05 | $-0.34 | $-0.20 | +41.2% |
| 2025-02-12 | $-0.27 | $-0.23 | +14.8% |
| 2024-11-07 | $-0.29 |
| $-0.22 |
| +24.1% |
| +1.17% |
| $3.6B |
| — |
| IRONDisc Medicine, Inc. | $68.92 | -1.63% | $2.6B | — |
| LEGNLegend Biotech Corporation | $18.53 | -0.59% | $3.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
$ADPT Some clown is stating that number of stocks available to short is shrinking rapidly so the stock price will drop. Huh?
View on StockTwits ↗
@TraderofTickers @theSnip3r $WOK started out with a market cap of something like $60M tops at listing date. I think most people expect those micro cap stocks to do the typical pump / dump / RS / rinse and repeat $ADPT started with a market cap of $2.2B, which to me gives it more legitimacy. But who knows.
View on StockTwits ↗
$ADPT some low volume minor ( I say minor because theres no real reason for it) consolidation, while some shorts quietly cover at a bargain (a painful bargain). Many bullish potential scenarios lurking. MM’s should be tweaking their algorithm even greater towards the long side… many bullish scenarios lurking… expanded medicare coverage (?) new indications from abstracts (?) buyouts (?) new opportunities from note $’s (?) Harlan giving away more shares at insanely low prices (contrarian indicator) expense consolidation (!)(?)
View on StockTwits ↗$ADPT some massive trades crossing off the tape. Volu well over 1 million.
View on StockTwits ↗
$ADPT sorry to sound aggressive just can’t find the adjustment… plus the 10cent number was barely mentioned (and the adj not mentioned at all). Seems it has been served at the upgrade party. Greaat quarter… ok talk to me later.
View on StockTwits ↗$ADPT so WTF is it! A ten or twenty five cent loss?
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-7-29-adaptive-biotechnologies-co-stock/ $ADPT Adaptive Biotechnologies Earnings Transcrip
View on StockTwits ↗
$ADPT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.25 down -47.06% YoY • Reported revenue of $71.55M up 21.53% YoY • Adaptive Biotechnologies expects full year MRD revenue between $268 million and $278 million, while total company operating expenses, including cost of revenue, are forecast between $350 million and $355 million.
View on StockTwits ↗
$ADPT I’d be thrilled at $30+. $34 would be a gift from God
View on StockTwits ↗$ADPT WOW! What’s with all the volume today??? Even a guess is appreciated
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.